Are you a medical practitioner? Yes, then you must be aware of Dublin, Ireland-based one of the world’s leading medical technology giant Medtronic plc (MDT - Free Report) which has a global reach that extends to more than 150 countries. Last year, more than 65 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its positive fourth-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.38 per share. Medtronic’s adjusted earnings per share of $1.42 exceeded this estimate by 2.9%.
Revenues: Medtronic posted revenues of $8.14 billion, beating the Zacks Consensus Estimate for revenues of $7.99 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 5.4% at constant exchange rate (CER) to $3.14 billion, revenues from Minimally Invasive Therapies Group declined 4.8% at CER to $2.24 billion. Revenues from Restorative Therapies Group rose 6.1% at CER to $2.13 billion, while revenues from Diabetes Group rose 21.3% at CER to $645 million.
Major Factors: Per management, fourth quarter performance was encouraging. Moreover, the company witnessing growth in all the business segments also buoys optimism.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on Medtronic's earnings report later!
Wall Street’s Next AmazonZacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Are you a medical practitioner? Yes, then you must be aware of Dublin, Ireland-based one of the world’s leading medical technology giant Medtronic plc (MDT - Free Report) which has a global reach that extends to more than 150 countries. Last year, more than 65 million people benefited from Medtronic’s medical therapies, which treat cardiac and vascular diseases, diabetes, and neurological and musculoskeletal conditions.
Currently, Medtronic has a Zacks Rank #3 (Hold) but that could change following its positive fourth-quarter fiscal 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate stands at $1.38 per share. Medtronic’s adjusted earnings per share of $1.42 exceeded this estimate by 2.9%.
Revenues: Medtronic posted revenues of $8.14 billion, beating the Zacks Consensus Estimate for revenues of $7.99 billion.
Key Stats: Revenues from Medtronic’s Cardiac and Vascular Group rose 5.4% at constant exchange rate (CER) to $3.14 billion, revenues from Minimally Invasive Therapies Group declined 4.8% at CER to $2.24 billion. Revenues from Restorative Therapies Group rose 6.1% at CER to $2.13 billion, while revenues from Diabetes Group rose 21.3% at CER to $645 million.
Major Factors: Per management, fourth quarter performance was encouraging. Moreover, the company witnessing growth in all the business segments also buoys optimism.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on Medtronic's earnings report later!
Wall Street’s Next AmazonZacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MDT - FREE